-
(2S)-2-[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanamido]-4-methylpentanoic acid
-
ChemBase ID:
72759
-
Molecular Formular:
C16H24N2O4
-
Molecular Mass:
308.37276
-
Monoisotopic Mass:
308.17360726
-
SMILES and InChIs
SMILES:
c1cccc(c1)C[C@H]([C@@H](C(=O)N[C@H](C(=O)O)CC(C)C)O)N
Canonical SMILES:
O[C@H](C(=O)N[C@H](C(=O)O)CC(C)C)[C@@H](Cc1ccccc1)N
InChI:
InChI=1S/C16H24N2O4/c1-10(2)8-13(16(21)22)18-15(20)14(19)12(17)9-11-6-4-3-5-7-11/h3-7,10,12-14,19H,8-9,17H2,1-2H3,(H,18,20)(H,21,22)/t12-,13+,14+/m1/s1
InChIKey:
VGGGPCQERPFHOB-RDBSUJKOSA-N
-
Cite this record
CBID:72759 http://www.chembase.cn/molecule-72759.html
NAMES AND DATABASE IDS
NAMES AND DATABASE IDS
Names Database IDs
IUPAC name
|
(2S)-2-[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanamido]-4-methylpentanoic acid
|
|
|
IUPAC Traditional name
|
|
Synonyms
|
([2S,3R]-3-Amino-2-hydroxy-4-phenylbutanoyl)-L-leucine
|
N-[(2S,3R)-3-Amino-2-hydroxy-4-phenylbutyryl]-L-leucine
|
N-[(2S,3R)-3-Amino-2-hydroxy-4-phenylbutyryl]-L-leucine
|
Bestatin
|
Ubenimex
|
([2S,3R]-3-氨基-2-羟基-4-苯基丁酰基)-L-亮氨酸
|
N-[(2S,3R)-3-氨基-2-羟基-4-苯基丁酰基]-L-亮氨酸
|
|
|
CAS Number
|
|
EC Number
|
|
MDL Number
|
|
PubChem SID
|
|
PubChem CID
|
|
CHEMBL
|
|
Wikipedia Title
|
|
DATA SOURCES
DATA SOURCES
All Sources Commercial Sources Non-commercial Sources
CALCULATED PROPERTIES
CALCULATED PROPERTIES
JChem
Acid pKa
|
3.7260025
|
H Acceptors
|
5
|
H Donor
|
4
|
LogD (pH = 5.5)
|
-1.1024202
|
LogD (pH = 7.4)
|
-1.1396116
|
Log P
|
-1.0995758
|
Molar Refractivity
|
82.0498 cm3
|
Polarizability
|
32.62761 Å3
|
Polar Surface Area
|
112.65 Å2
|
Rotatable Bonds
|
8
|
Lipinski's Rule of Five
|
true
|
DETAILS
DETAILS
Selleck Chemicals
Wikipedia
Sigma Aldrich
Selleck Chemicals -
S1591
|
Research Area: Cancer Biological Activity: Ubenimex is a competitive aminopeptidase B inhibitor with an IC50 of 100 mg/ml for K562 cells. Proliferation of all the cell lines except KG1 was inhibited by bestatin. P39/TSU, HL60 and U937 were highly sensitive, with 50% growth inhibitory concentrations (IC50) close to the maximum serum concentration when bestatin was orally administered at 30 mg in clinical application. All cell lines except for K562 highly expressed CD13, but a clear correlation between the sensitivity to bestatin and expression of CD13 was not observed. Other aminopeptidase inhibitors such as amastatin A, arphamenine B and WM15 antibody showed no growth inhibitory effects. [1]References on Ubenimex (Bestatin)[1] http://en.wikipedia.org/wiki/Ubenimex, , |
PATENTS
PATENTS
PubChem Patent
Google Patent